Safety and Efficacy of Baseline Antiplatelet Treatment in
Patients Undergoing Mechanical Thrombectomy for Ischemic
Stroke: Antiplatelets Before Mechanical Thrombectomy

J 2023

Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy

KLAIL, Tomáš, Petra ŠEDOVÁ, Jan VINKLÁREK, Ingrid KOVACOVA, Michal BAR et. al.

Základní údaje

Originální název

Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy

Autoři

KLAIL, Tomáš (203 Česká republika, domácí), Petra ŠEDOVÁ (203 Česká republika, domácí), Jan VINKLÁREK (203 Česká republika, domácí), Ingrid KOVACOVA (203 Česká republika), Michal BAR (203 Česká republika), Filip CIHLAR (203 Česká republika), David CERNIK (203 Česká republika), Lubomir KOCI (203 Česká republika), René JURA (203 Česká republika, domácí), Roman HERZIG (203 Česká republika), Jakub HUSTÝ (203 Česká republika, domácí), Martin KOCHER (203 Česká republika), Martin KOVAR (203 Česká republika), Miroslava NEVSIMALOVA (203 Česká republika), Jan RAUPACH (203 Česká republika), Miloslav ROCEK (203 Česká republika), Daniel SANAK (203 Česká republika), Petr SEVCIK (203 Česká republika), David SKOLOUDIK (203 Česká republika), Martin SRAMEK (203 Česká republika), Jiří VANÍČEK (203 Česká republika, domácí), Peter VASKO (203 Česká republika), Daniel VACLAVIK (203 Česká republika), Ales TOMEK (203 Česká republika) a Robert MIKULÍK (203 Česká republika, garant, domácí)

Vydání

Journal of vascular and interventional radiology, New York, ELSEVIER, 2023, 1051-0443

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.900 v roce 2022

Kód RIV

RIV/00216224:14110/23:00131949

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.jvir.2023.05.017

UT WoS

001068364800001

Klíčová slova česky

THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES

Klíčová slova anglicky

THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES

Štítky

14110119, 14110127, 14110132, 14110211, 14110216, Excelence Science, FNUSA, MU, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 5. 4. 2024 08:50, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: To investigate the safety and efficacy of baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT). Materials and Methods: Baseline use of antiplatelet medication before MT for (AIS) may provide benefit on reperfusion and clinical outcome but could also carry an increased risk of intracranial hemorrhage (ICH). All consecutive patients with AIS and treated with MT with and without intravenous thrombolysis (IVT) between January 2012 and December 2019 in all centers performing MT nationwide were reviewed. Data were prospectively collected in national registries (eg, SITS-TBY and RES-Q). Primary outcome was functional independence (modified Rankin Scale 0-2) at 3 months; secondary outcome was ICH. Results: Of the 4,351 patients who underwent MT, 1,750 (40%) and 666 (15%) were excluded owing to missing data from the functional independence and ICH outcome cohorts, respectively. In the functional independence cohort (n = 2,601), 771 (30%) patients received antiplatelets before MT. Favorable outcome did not differ in any antiplatelet, aspirin, and clopidogrel groups when compared with that in the no-antiplatelet group: odds ratio (OR), 1.00 (95% CI, 0.84-1.20); OR, 1.05 (95% CI, 0.86-1.27); and OR, 0.88 (95% CI, 0.55-1.41), respectively. In the ICH cohort (n = 3,685), 1095 (30%) patients received antiplatelets before MT. The rates of ICH did not increase in any treatment options (any antiplatelet, aspirin, clopidogrel, and dual antiplatelet groups) when compared with those in the no-antiplatelet group: OR, 1.03 (95% CI, 0.87-1.21); OR, 0.99 (95% CI, 0.83-1.18); OR, 1.10 (95% CI, 0.82-1.47); and OR, 1.43 (95% CI, 0.87-2.33), respectively. Conclusions: Antiplatelet monotherapy before MT did not improve functional independence or increase the risk of ICH.

Návaznosti

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

KLAIL, Tomáš, Petra ŠEDOVÁ, Jan VINKLÁREK, Ingrid KOVACOVA, Michal BAR, Filip CIHLAR, David CERNIK, Lubomir KOCI, René JURA, Roman HERZIG, Jakub HUSTÝ, Martin KOCHER, Martin KOVAR, Miroslava NEVSIMALOVA, Jan RAUPACH, Miloslav ROCEK, Daniel SANAK, Petr SEVCIK, David SKOLOUDIK, Martin SRAMEK, Jiří VANÍČEK, Peter VASKO, Daniel VACLAVIK, Ales TOMEK a Robert MIKULÍK. Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy. Journal of vascular and interventional radiology. New York: ELSEVIER, 2023, roč. 34, č. 9, s. "1502"-"1512.e12", 21 s. ISSN 1051-0443. Dostupné z: https://dx.doi.org/10.1016/j.jvir.2023.05.017.

@article{2327097,
   author = {Klail, Tomáš and Šedová, Petra and Vinklárek, Jan and Kovacova, Ingrid and Bar, Michal and Cihlar, Filip and Cernik, David and Koci, Lubomir and Jura, René and Herzig, Roman and Hustý, Jakub and Kocher, Martin and Kovar, Martin and Nevsimalova, Miroslava and Raupach, Jan and Rocek, Miloslav and Sanak, Daniel and Sevcik, Petr and Skoloudik, David and Sramek, Martin and Vaníček, Jiří and Vasko, Peter and Vaclavik, Daniel and Tomek, Ales and Mikulík, Robert},
   article_location = {New York},
   article_number = {9},
   doi = {http://dx.doi.org/10.1016/j.jvir.2023.05.017},
   keywords = {THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES},
   language = {eng},
   issn = {1051-0443},
   journal = {Journal of vascular and interventional radiology},
   title = {Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy},
   url = {https://www.sciencedirect.com/science/article/pii/S1051044323003494?via%3Dihub},
   volume = {34},
   year = {2023}
}

TY  - JOUR
ID  - 2327097
AU  - Klail, Tomáš - Šedová, Petra - Vinklárek, Jan - Kovacova, Ingrid - Bar, Michal - Cihlar, Filip - Cernik, David - Koci, Lubomir - Jura, René - Herzig, Roman - Hustý, Jakub - Kocher, Martin - Kovar, Martin - Nevsimalova, Miroslava - Raupach, Jan - Rocek, Miloslav - Sanak, Daniel - Sevcik, Petr - Skoloudik, David - Sramek, Martin - Vaníček, Jiří - Vasko, Peter - Vaclavik, Daniel - Tomek, Ales - Mikulík, Robert
PY  - 2023
TI  - Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy
JF  - Journal of vascular and interventional radiology
VL  - 34
IS  - 9
SP  - "1502"-"1512.e12"
EP  - "1502"-"1512.e12"
PB  - ELSEVIER
SN  - 10510443
KW  - THERAPYTHROMBOLYSISMETAANALYSISGUIDELINESOUTCOMES
UR  - https://www.sciencedirect.com/science/article/pii/S1051044323003494?via%3Dihub
N2  - Purpose: To investigate the safety and efficacy of baseline antiplatelet treatment in patients with acute ischemic stroke (AIS) undergoing mechanical thrombectomy (MT). Materials and Methods: Baseline use of antiplatelet medication before MT for (AIS) may provide benefit on reperfusion and clinical outcome but could also carry an increased risk of intracranial hemorrhage (ICH). All consecutive patients with AIS and treated with MT with and without intravenous thrombolysis (IVT) between January 2012 and December 2019 in all centers performing MT nationwide were reviewed. Data were prospectively collected in national registries (eg, SITS-TBY and RES-Q). Primary outcome was functional independence (modified Rankin Scale 0-2) at 3 months; secondary outcome was ICH. Results: Of the 4,351 patients who underwent MT, 1,750 (40%) and 666 (15%) were excluded owing to missing data from the functional independence and ICH outcome cohorts, respectively. In the functional independence cohort (n = 2,601), 771 (30%) patients received antiplatelets before MT. Favorable outcome did not differ in any antiplatelet, aspirin, and clopidogrel groups when compared with that in the no-antiplatelet group: odds ratio (OR), 1.00 (95% CI, 0.84-1.20); OR, 1.05 (95% CI, 0.86-1.27); and OR, 0.88 (95% CI, 0.55-1.41), respectively. In the ICH cohort (n = 3,685), 1095 (30%) patients received antiplatelets before MT. The rates of ICH did not increase in any treatment options (any antiplatelet, aspirin, clopidogrel, and dual antiplatelet groups) when compared with those in the no-antiplatelet group: OR, 1.03 (95% CI, 0.87-1.21); OR, 0.99 (95% CI, 0.83-1.18); OR, 1.10 (95% CI, 0.82-1.47); and OR, 1.43 (95% CI, 0.87-2.33), respectively. Conclusions: Antiplatelet monotherapy before MT did not improve functional independence or increase the risk of ICH.
ER  -

KLAIL, Tomáš, Petra ŠEDOVÁ, Jan VINKLÁREK, Ingrid KOVACOVA, Michal BAR, Filip CIHLAR, David CERNIK, Lubomir KOCI, René JURA, Roman HERZIG, Jakub HUSTÝ, Martin KOCHER, Martin KOVAR, Miroslava NEVSIMALOVA, Jan RAUPACH, Miloslav ROCEK, Daniel SANAK, Petr SEVCIK, David SKOLOUDIK, Martin SRAMEK, Jiří VANÍČEK, Peter VASKO, Daniel VACLAVIK, Ales TOMEK a Robert MIKULÍK. Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy. \textit{Journal of vascular and interventional radiology}. New York: ELSEVIER, 2023, roč.~34, č.~9, s.~''1502''-''1512.e12'', 21 s. ISSN~1051-0443. Dostupné z: https://dx.doi.org/10.1016/j.jvir.2023.05.017.

Podrobný výpis o publikaci